Breast cancer drug could hold the key to fighting other tumours

December 5, 2012
Breast cancer drug could hold the key to fighting other tumours
Credit: Shutterstock

New research out of the United Kingdom is showing that a common drug used in the fight against breast cancer could also be employed in the fight against other tumours. The drug in question is geldanamycin, and has made a name for itself for its ability to attack a protein associated with the spread of breast cancer. More recently, however, a laboratory-based study has discovered that it can also degrade a different protein that triggers blood vessel growth. These results were published in the journal PLOS ONE.

According to Dr Sreenivasan Ponnambalam, reader in human disease biology in the University of Leeds' Faculty of Biological Sciences, one of the major challenges facing in the battle against cancer is stopping unwanted . He went on to explain the significance of their results: 'This is potentially very significant because tumours secrete substances that stimulate blood vessels to develop around them, forming networks that supply nutrients and provide pathways for spread around the body.'

Dr Ponnambalam further noted, 'This is one of the big problems in cancer: how can we stop the growing and spreading through these blood vessel networks?'

Geldanamycin is not the only drug currently available that tries to stop this type of growth; there are other drugs available, but they have certain risks associated with them. One type tries to attack directly the membrane protein VEGFR2, which is essential for new blood vessel growth. However, that approach carries the risk of serious side-effects because proteins in the membrane walls of blood vessels do important work such as controlling blood pressure.

The importance of their finding is that geldanamycin on the other hand offers a novel and potentially safer solution because it suppresses the protein indirectly. The new study, which was based on experiments with and different animal models, discovered that geldanamycin indirectly triggered the clearance of the VEGFR2 protein by activating a cellular quality control system that breaks down many proteins. That quality control system already degrades VEGFR2 relatively slowly but the drug accelerates the process, preventing activation of the protein and inappropriate new blood vessel formation.

'With conventional treatments, we have been trying to deal with the situation after the switch has been thrown. What this drug does is destroy the key part of the switch before that switch is thrown,' Dr Ponnambalam said. 'Geldanamycin and chemical derivatives have been under intensive study in the laboratory and in clinical trials for the past 20 years. The cost to the NHS or patients could be relatively low compared to the expensive existing anti-cancer drugs, which are still under patent,' Dr Ponnambalam added.

With such benefits, the team is eager to continue their research which was supported by the Wellcome Trust, the British Heart Foundation, a BBSRC-CASE PhD Studentship Award, and a University of Leeds ORSAS Tetley & Lupton PhD Scholarship.

Explore further: Breast cancer drug geldanamycin could halt other tumors

Related Stories

Breast cancer drug geldanamycin could halt other tumors

November 6, 2012
A drug commonly used in treating breast cancer could have far wider benefits, offering a new way of preventing cancers spreading through the body, according to a University of Leeds-led study.

Culprit behind unchecked angiogenesis identified

March 29, 2012
German researchers unravel a critical regulatory mechanism controlling blood vessel growth that might help solve drug resistance problems in the future.

New strategy to attack tumor-feeding blood vessels

June 6, 2011
Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

Finding could lead to reduced side effects in anti-cancer antibiotics

June 28, 2011
Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used ...

Recommended for you

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.